Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2025Open Access

Contemporary Use of Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKaren Hoi Lam LiQueen Mary HospitalRLRoland LeungQueen Mary HospitalBLBryan Cho Wing LiUniversity of Hong Kong

Discussion

Loading...

Member takes

Overview

Review discusses immunotherapy combinations showing improved outcomes in patients with advanced HCC, highlighting the role of predictive biomarkers.

Key Points

  • Immunotherapy improves treatment outcomes for advanced hepatocellular carcinoma, enhancing anti-tumour immunity.
  • Clinical trials of ICI-based combinations have outperformed traditional therapies, supporting an evolving treatment paradigm.
  • Understanding the hepatic tumour microenvironment remains critical for developing effective immunotherapy combinations.
  • Increased toxicity and costs with new immunotherapy strategies highlight the need for further research on predictive biomarkers.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d7be62eebfec0fc5237b58https://doi.org/10.20944/preprints202509.1985.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma2025
  2. 2Recent advance in immune checkpoint inhibitors-based therapy of advanced hepatocellular carcinoma2024
  3. 3Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma2024 · 36 citations
  4. 4The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma2026
  5. 5Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances2026